摘要
目的探究谷红注射液联合替格瑞洛治疗急性心肌梗死(AMI)的临床效果。方法选取2021年1月至2022年12月焦作煤业(集团)有限责任公司中心医院收治的92例AMI患者,按照随机数字表法分为研究组、对照组,各46例。两组均接受常规药物治疗,对照组接受替格瑞洛治疗,研究组在对照组基础上增加谷红注射液治疗,两组连续治疗2周。比较两组临床疗效、治疗前后心功能指标[左室射血分数(LVEF)、左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)]、血液流变学指标[红细胞压积(HCT)、全血低切黏度(LBV)、血浆黏度(PV)、全血高切黏度(HBV)]、蛋白激酶(PKG)信号通路相关指标[环磷酸鸟苷(cGMP)、PKG]及不良反应发生率。结果研究组临床总有效率高于对照组(P<0.05),LVEF、cGMP、PKG高于对照组,LVESD、LVEDD、HCT、HBV、PV、LBV低于对照组(P<0.05)。两组不良反应发生率差异无统计学意义(P>0.05)。结论谷红注射液联合格瑞洛治疗AMI效果确切,可促进心功能及血液流变学改善,且有一定安全性。
Objective To investigate the clinical effect of Guhong injection combined with ticagrelor in the treatment of Acute myocardial infarction(AMI).Methods A total of 92 patients with AMI treated in Jiaozuo Coal Industry(Group)Co.,Ltd.Central Hospital from January 2021 to December 2022 were selected and divided into study group and control group with 46 cases each by random number table method.Both groups received conventional drug treatment,the control group received ticagrelor,and study group received grain Guhong injection on the basis of control group.Both groups were treated continuously for 2 weeks.The clinical efficacy,cardiac function indexes[left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD)],hemorheology indexes(HCT),whole blood low tangential viscosity(LBV),plasma viscosity(PV),whole blood high tangential viscosity(HBV),protein kinase(PKG)signaling pathway related indicators[cyclic guanosine phosphate(cGMP),PKG]and the incidence of adverse reactions before and after treatment were compared between the two groups.Results The total clinical effective rate of the research group was higher than that of the control group(P<0.05),LVEF,cGMP,and PKG were higher than those of the control group,and LVESD,LVEDD,HCT,HBV,PV,and LBV were lower than those of the control group(P<0.05).There was no statistically difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The combination of Guhong injection and Grello has a definite effect in the treatment of AMI,which can promote the improvement of heart function and hemorheology,and has a certain degree of safety.
作者
张学辉
林玉兰
ZHANG Xuehui;LINYulan(Jiaozuo Coal Industry(Group)Co.,Ltd.Central Hospital,Jiaozuo 454000,China)
出处
《河南医学研究》
CAS
2024年第19期3585-3589,共5页
Henan Medical Research
关键词
谷红注射液
替格瑞洛
急性心肌梗死
蛋白激酶信号通路
心脏功能
Guhong injection
ticagrelor
acute myocardial infarction
protein kinase signaling pathway
cardiac function